CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review

August 2021 | 44 pages | ID: C49085EBA50EN
GlobalData

Abstracts

CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CytRx Corp (CytRx) is a biopharmaceutical company that focuses on the discovery and development of new therapeutics for the treatment of cancer and neurodegenerative diseases. CytRx’s product candidate, aldoxorubicin, is in the late stage of clinical development, and finds application in treating relapsed soft tissue melanoma, small-cell lung cancer, and other types of cancer with unmet medical needs. The company also has other pipeline products being developed through linkeractivated drug release technology platform. It has milestone and royalty agreements with Orphazyme A/S and NantCell, Inc. (now ImmunityBio, Inc.), which could generate substantial revenue for the company. CytRx is headquartered in Los Angeles, California, the US.

CytRx Corp Key Recent Developments

Aug 12,2021: CytRx Comments on Quarterly Results and Recent Strategic Initiatives
Jul 29,2021: CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
Mar 04,2021: CytRx highlights Orphazyme’s appointment of new CEO ahead of potential regulatory approval of arimoclomol for Niemann-Pick Disease Type C
Mar 03,2021: CytRx to Participate in Upcoming Investor Conferences
Nov 16,2020: CytRx comments on quarterly results and recent strategic progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

CytRx Corp - Key Facts
CytRx Corp - Key Employees
CytRx Corp - Key Employee Biographies
CytRx Corp - Major Products and Services
CytRx Corp - History
CytRx Corp - Company Statement
CytRx Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
CytRx Corp - Business Description
CytRx Corp - SWOT Analysis
SWOT Analysis - Overview
CytRx Corp - Strengths
CytRx Corp - Weaknesses
CytRx Corp - Opportunities
CytRx Corp - Threats
CytRx Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CytRx Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 12, 2021: CytRx Comments on Quarterly Results and Recent Strategic Initiatives
Jul 29, 2021: CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
Mar 04, 2021: CytRx highlights Orphazyme’s appointment of new CEO ahead of potential regulatory approval of arimoclomol for Niemann-Pick Disease Type C
Mar 03, 2021: CytRx to Participate in Upcoming Investor Conferences
Nov 16, 2020: CytRx comments on quarterly results and recent strategic progress
Aug 24, 2020: CytRx announces initiatives to strengthen corporate governance and support strategic priorities
Mar 10, 2020: CytRx provides update on management change
Jan 09, 2020: CYTRX: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

CytRx Corp, Key Facts
CytRx Corp, Key Employees
CytRx Corp, Key Employee Biographies
CytRx Corp, Major Products and Services
CytRx Corp, History
CytRx Corp, Subsidiaries
CytRx Corp, Key Competitors
CytRx Corp, Ratios based on current share price
CytRx Corp, Annual Ratios
CytRx Corp, Annual Ratios (Cont...1)
CytRx Corp, Interim Ratios
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CytRx Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

CytRx Corp, Performance Chart (2016 - 2020)
CytRx Corp, Ratio Charts
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021